NVS - Novartis AG
| Previous Close | 76.99 |
| Open | 76.24 |
| Bid | 76.76 x 2200 |
| Ask | 76.82 x 1700 |
| Day's Range | 75.73 - 76.56 |
| 52 Week Range | 75.73 - 94.19 |
| Volume | 1,294,357 |
| Avg. Volume | 1,833,059 |
| Market Cap | 179.032B |
| Beta | 0.88 |
| PE Ratio (TTM) | 23.51 |
| EPS (TTM) | 3.25 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.98 (3.87%) |
| Ex-Dividend Date | 2018-03-06 |
| 1y Target Est | 98.06 |
- InvestorPlace•16 hours ago
5 Biotech ETFs for Outsized Gains
The healthcare sector, the third-largest sector allocation in the S&P 500, is usually viewed as a defensive space, but within the space lie plenty of growth opportunities — and much of the healthcare sector’s growth appeal comes by way of biotechnology stocks.
- Market Realist•16 hours ago
Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release
In 1Q18, analysts expect Sanofi’s (SNY) revenue to fall ~6.6% YoY (year-over-year) to 8.1 billion euros from 8.7 billion euros, and its earnings per share to fall to 1.13 euros from 1.42 euros. Sanofi’s stock price has fallen ~9.4% over the last 12 months and ~7.1% year-to-date. Analysts’ price target of $47.67 suggests the stock could return ~19.2% over the next 12 months based on its price of $39.95 on April 23.
Market Realist•16 hours agoNovartis Delivered Strong Performance in 1Q18
Novartis (NVS) delivered a strong performance in the first quarter of fiscal 2018. Its net sales grew 4% to $12.7 billion, driven by higher product sales of Entresto, Cosentyx, and oncology products. Entresto sales grew to $200 million, driven by higher worldwide uptake. Cosentyx sales grew 35% to $580 million due to expanded access and a strong growth in all indications.
- Market Realist•19 hours ago
GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings
GlaxoSmithKline (GSK) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues for 1Q18. The above chart compares the quarterly revenues and EPS for GlaxoSmithKline since 1Q17. GlaxoSmithKline reported revenues of 7.2 billion pounds in 1Q18, a 2% decline in revenues, compared to 7.4 billion pounds in 1Q17.
- Market Realist•19 hours ago
Novartis Launches FocalView to Modernize Clinical Trials
Novartis (NVS), a leading pharmaceutical company, includes therapies for retinal disorders, dry eyes, glaucoma, and other eye disorders in its ophthalmology portfolio. On April 25, Novartis launched FocalView, an ophthalmic digital research app created with the help of Apple’s ResearchKit.
Market Realist•19 hours agoAmgen’s Earnings Grow 12% Year-Over-Year in 1Q18
In 1Q18, Amgen (AMGN) generated revenue of $5.6 billion, representing ~2% YoY (year-over-year) growth from its revenue of $5.5 billion in 1Q17. Quarter-over-quarter, its revenue fell ~4%. Amgen’s GAAP (generally accepted accounting principles) operating income and net income rose ~5% and ~12% YoY, respectively, to $2.7 billion and $2.3 billion from $2.6 billion and $2.1 billion.
Market Realist•21 hours agoGilead Sciences has a Strong Oncology Research Program
Gilead Sciences (GILD) is currently studying a combination of anti-MMP-9 (anti-matrix metalloproteinase-9) antibody andecaliximab with modified FOLFOX 6 in a Phase 3 trial as a therapy for treatment-naïve advanced gastric or GAMMA-1 (gastroesophageal junction adenocarcinoma) patients. The company also expects to conclude its Phase 2 trial comparing an andecaliximab-nivolumab combination with a nivolumab monotherapy in gastric cancer in 2018. If these trials prove successful, Gilead Sciences could emerge as major competition for other gastric cancer therapy players such as Eli Lilly (LLY) and Roche (RHHBY).
- Zacks•22 hours ago
The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay
The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay
- Zacks•22 hours ago
Glaxo (GSK) Misses on both Earnings and Revenue in Q1
Glaxo's (GSK) Q1 earnings and revenue miss estimates. In the event of introduction of Advair generic in the U.S. market by mid-year, Glaxo expects adjusted EPS to be flat to down at CER in 2018.
Reuters•yesterdayNovartis' digital drive continues with eye-disease app
Novartis's foray into digital technology intensified on Wednesday as the Swiss drugmaker launched a mobile-phone based app to help collect data from people participating in eye disease studies. It is using Apple's ResearchKit for its "FocalView" application to help researchers track ophthalmic disease progression by collecting data directly from patients without requiring them to travel to a doctor. As Chief Executive Vas Narasimhan focuses the Basel-based company on innovative medicines via acquisitions like this month's $8.7 billion takeover of U.S.-based AveXis, he is also plowing resources into digital technology in a bid to boost trial success, save time and cut costs.
Reuters•yesterdayNovartis' digital drive continues with eye-disease app
Novartis's foray into digital technology intensified on Wednesday as the Swiss drugmaker launched a mobile-phone based app to help collect data from people participating in eye disease studies. It is using Apple's ResearchKit for its "FocalView" application to help researchers track ophthalmic disease progression by collecting data directly from patients without requiring them to travel to a doctor. As Chief Executive Vas Narasimhan focuses the Basel-based company on innovative medicines via acquisitions like this month's $8.7 billion takeover of U.S.-based AveXis, he is also plowing resources into digital technology in a bid to boost trial success, save time and cut costs.
- Reuters•yesterday
Novartis' digital drive continues with eye-disease app
Novartis's foray into digital technology intensified on Wednesday as the Swiss drugmaker launched a mobile-phone based app to help collect data from people participating in eye disease studies. It is using Apple's ResearchKit for its "FocalView" application to help researchers track ophthalmic disease progression by collecting data directly from patients without requiring them to travel to a doctor. As Chief Executive Vas Narasimhan focuses the Basel-based company on innovative medicines via acquisitions like this month's $8.7 billion takeover of U.S.-based AveXis, he is also plowing resources into digital technology in a bid to boost trial success, save time and cut costs.
- The Wall Street Journal•yesterday
[$$] How Long Till the Final World Malaria Day?
Wiping the disease out by 2040 could save 11 million lives.
- Zacks•2 days ago
Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley
Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley
- Forbes•2 days ago
Is Biopharma Investing Too Much In Cancer R&D?
Jay Bradner is the president of Novartis’ Institutes for BioMedical Research, the organization entrusted with Novartis’ R&D budget of $9 billion -- one of the largest in the industry. Furthermore, Novartis is a leading innovator in the oncology field with targeted therapies as well as the recently launched CAR-T therapy Kymriah for a deadly childhood leukemia. This is a time of extraordinary promise for cancer medicine, with unambiguous evidence of progress in the innovation of both targeted and immune-oncology therapies.
- Zacks•6 days ago
Shire (SHPG) Turns Down Takeda's Third Buyout Proposition
Shire (SHPG) declines Takeda Pharmaceutical's third acquisition offer in a cash-stock deal.
- Zacks•6 days ago
What's in the Cards for Glaxo (GSK) This Earnings Season?
Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.
- Zacks•6 days ago
Novartis (NVS) Reports Encouraging Data on MS Candidate
Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.
- Zacks•6 days ago
Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.
- Zacks•6 days ago
J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?
Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.
- Investor's Business Daily•7 days ago
Novartis Stock Dips After Cosentyx Sales, Sandoz Generics Disappoint
Novartis beat earnings and revenue forecasts, but generics revenue tumbled and a key drug missed sales estimates.
- InvestorPlace•7 days ago
Novartis AG (ADR) Stock Drops on Q1 Earnings Miss
Novartis AG (ADR) (NYSE:NVS) stock took a hit on Thursday following the release of its earnings report for the first quarter of 2018.Source: Shutterstock
Motley Fool•7 days agoNovartis AG (NVS) Q1 2018 Earnings Conference Call Transcript
NVS earnings call for the period ending March 31, 2018.
- Zacks•7 days ago
Novartis (NVS) Beats Earnings and Revenue Estimates in Q1
Novartis reported encouraging results for the first quarter as sales and earnings both topped expectations on Cosentyx and Entresto strength.
- PR Newswire•7 days ago
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of AveXis, Inc. - AVXS
NEW YORK , April 19, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
